SCHEMBL28774233

SCHEMBL28774233

CC=CN(C(N)=O)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 1/20 0.39
▸ ALOX5 P09917 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.37
▸ TSHR P16473 2/20 0.37
▸ GLA P06280 1/20 0.37
▸ RECQL P46063 3/20 0.35
▸ MAPT P10636 3/20 0.35
▸ POLB P06746 2/20 0.35
▸ BLM P54132 2/20 0.35
▸ CYP3A4 P08684 2/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ PARP1 P09874 1/20 0.35
▸ PMP22 Q01453 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1416007 0.84 NPSR1 (0.41) NPSR1ALOX5ALDH1A1TSHRGLA
SCHEMBL13144272 0.82 KMT2A (0.48) NPSR1ALDH1A1TSHRGLARECQL
SCHEMBL15786490 0.82 NPSR1 (0.40) NPSR1ALOX5ALDH1A1TSHRGLA
SCHEMBL3258421 0.78 NPSR1 (0.43) NPSR1ALOX5ALDH1A1TSHRGLA
SCHEMBL11074660 0.76 NPSR1 (0.41) NPSR1ALOX5ALDH1A1TSHRGLA
SCHEMBL19957298 0.76 MEN1 (0.36) NPSR1ALDH1A1TSHRGLARECQL
SCHEMBL27867642 0.74 MEN1 (0.37) NPSR1ALDH1A1TSHRRECQLCYP3A4
SCHEMBL10348319 0.73 NPSR1 (0.39) NPSR1ALOX5ALDH1A1TSHRGLA
SCHEMBL23869841 0.69 MEN1 (0.33) ALDH1A1RECQLMAPTPOLBBLM
SCHEMBL1630634 0.69 KMT2A (0.50) NPSR1ALOX5POLBL3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101238131-A Bridged piperazine and piperidine derivatives as CCR1 antagonists NOVARTIS AG (CH) 2008-08-06 — — CN disclosed
Send feedback